

PCR-/NAT *Clostridium difficile*
(RV 545) Mai / Juni 2018



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.

Sample composition and expected results.

	<i>Erwartet / expected</i>		<i>Probenzusammensetzung / Sample composition</i>
1815451	+++	61 / 71,72	<i>Clostridium difficile</i> (~ 1x10 ⁵ CFU/mL)
1815452	++	61 / 71,72	<i>Clostridium difficile</i> (~ 1x10 ⁴ CFU/mL)
1815453	∅	62	<i>Escherichia coli</i> K12
1815454	∅	62	<i>Escherichia coli</i> K12

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.

Absolute numbers of reported individual results.

<i>n = 154</i>	<i>Probennummer (Sample no.)</i>				<i>Inhibition</i>				
	1815451	1815452	1815453	1815454	1815451	1815452	1815453	1815454	
Befund <i>Result</i>									
Positiv	154	154	0	0	n.d.	0	0	0	0
Negativ	0	0	152	153	nein <i>no</i>	154	154	154	154
Fraglich <i>Questionable</i>	0	0	2	1	ja <i>yes</i>	0	0	0	0

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwendern verschiedener Methoden.

Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number *)	NAT richtig positiv <i>True positive results</i>			NAT richtig negativ <i>True negative results</i>		
	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%
Cepheid Xpert <i>C.difficile</i> [20] (n=53)	106	106 / 106	100	106	106 / 106	100
BD MAX <i>C.difficile</i> [21] (n=18)	36	36 / 36	100	36	36 / 36	100
r-Biopharm RIDAGENE Cdif [22] (n=23)	46	46 / 46	100	46	46 / 46	100
Commercial assay / kit [27] (n=45)	90	90 / 90	100	87	87 / 87 §	100
<i>In house</i> PCR assay [28] (n=16)	32	32 / 32	100	32	32 / 32	100
Andere / k.A. / other [29] (n=5)	10	10 / 10	100	10	10 / 10	100

§ Due to reporting questionable results, the number of true results (denominator in the „relative“ column) has been reduced.

* Durch Mehrfachnennung oder fehlende Angabe kann die absolute Zahl der Ergebnisse (Tab. 4) von der Anzahl der Teilnehmer abweichen.
 Due to reporting results of multiple assay systems or missing specifications, the effective numbers are not correlating with the number of participants.